 |
||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
 |
 |
 |
 |
|
 |
|
||||||
|
|
|
||||||||||||||
|
2000 News + Events |
|||||
Dr. Clinton Rubin wins 2000 Giovanni Borelli Award |
||||||
|
American Society of Biomechanics awards its highest honor to Dr. Clinton Rubin, Director, Center for Biotechnology The American Society of Biomechanics will present Dr. Rubin with its highest award of honor, the 2000 Giovanni Borelli Award, at the 24th Annual Meeting of the American Society of Biomechanics (ASB), to be held in Chicago on July 19-22, 2000. The Borelli Award recognizes outstanding career accomplishment and is awarded annually to an investigator who has conducted exemplary research in any area of biomechanics. Dr. Rubin’s research focuses on the molecular, cellular and tissue level mechanisms involved in the physical control of bone growth, healing, and homeostasis, and how these mechanisms can be utilized in the diagnosis, prevention and treatment of skeletal disease and injury. The National Institutes of Health, the National Aeronautics and Space Administration, Exogen, Inc., Millennium Pharmaceuticals and the New York Office of Science, Technology and Academic Research currently fund this work. Since 1997, the Center for Biotechnology has been lead by Dr. Clinton T. Rubin, Director. His strategic vision to fully capitalize upon the intellectual property resources of our State’s universities for the purpose of economic development has been a primary focus of the Center’s activities for the last three years. Dr. Rubin is a Professor of Orthopedics, Anatomy and Biomedical Engineering in the School of Medicine and College of Engineering and Applied Sciences. In addition, as founder of the Department of Biomedical Engineering at SUNY Stony Brook, Dr. Rubin is committed to harnessing Stony Brook’s unique resources to create a rigorous, cross-disciplinary training and research environment for graduate students. Dr. Rubin has also been instrumental in helping to set up the University MicroArray Facility (IMF) at SUNY Stony Brook. Under the leadership of Dr. Rubin, the Center will help advance custom cDNA spotting microarray capabilities, in cooperation with the School of Medicine and the American Medical Development Corporation. The IMF will serve as a regional center for DNA MicroArray efforts. Dr. Rubin’s accomplishments in basic science are reinforced with his commitment to industry and the private sector. He is the founder of Exogen, a medical device company focused on the biophysical modulation and treatment of musculoskeletal injuries and disease, which holds the FDA’s only approved device for the acceleration of fracture healing. After going public, Exogen was subsequently purchased by the multinational firm of Smith & Nephew. Dr. Rubin holds seven patents with six additional patents pending. His entrepreneurial skills are well suited to the ambitious economic development agenda of the Center, from workforce development to company creation. Dr. Rubin graduated from Harvard with a BA in Physiology
and a PhD in Anatomy from the University of Bristol, UK. Among his other
honors, he is the recipient of the National Science Foundation’s Presidential
Young Investigator Award, the American Society of Bone and Mineral Research
Fuller Albright award, and the Kappa Delta award from the American Academy
of Orthopaedic Surgeons. Dr. Rubin sits on the Board of Directors for
the New York Biotechnology Association. Genentech Awarded 2000 Helix Award for Corporate Excellence Genentech, Inc. received the 2000 Helix Award at the BIO 2000 International Biotechnology Meeting and Exhibition held in Boston on March 28, 2000. "We are honored to receive this award and to know that our efforts to meet unmet medical needs, as well as our leadership in our industry are being recognized in this way", said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. The award was presented by Dr. Clinton Rubin, Director of the Center for Biotechnology to Herbert W. Boyer , co-founder of Genentech, Inc. "The Long Island biotech community is proud to promote the highest standards of achievement among biotech companies", said Clinton T. Rubin, director, Center for Biotechnology.
Genetech, Inc. is a leading biotechnology company using human genetic information to develop, manufacture and market pharmaceuticals that address significant unmet medical needs. To date, the Company has developed 8 protein-based pharmaceuticals with 16 approved indications from breast cancer and lymphoma to heart attack and stroke. The Company has 18 product trials in development - 7 in Phase III clinical tirals, 6 in Phase II clinical trials and 3 in Phase I clinical trials - with one product being prepared for FDA approval and one awaiting FDA approval. During 1999 alone, the Company published 250 scientific papers and filed aproximately 550 patent applications worldwide. In 1980, Genetech clearly focused the spotlight on the biotechnology industry with its wildly successful IPO. In 1999, the Company did a reoffering of its shares in what is considered the largest public offering in the history of the U.S health care industry. This was quickly followed in October 1999 by the largest secondary offerting in U.S history - 20 million shares at $143 a share. The Company's market capitalization stands at nearly $40 billion. The company employs over 4,000 individuals and invests over $370 million a year in research and development. For more information, please visit www.helixaward.com
Stony Brook to Create DNA Microarray Center The School of Medicine and the Center for Biotechnology at the State University of New York at Stony Brook have announced plans to create a regional center for DNA microarray efforts. April 6th- STONY BROOK, NY. Dr. Norman H. Edelman, Vice-President for Health Sciences and Dean of the Medical School, announced the formal agreement with the American Medical Development Corporation (AMDeC) to establish an DNA Microarray Facility at Stony Brook using a platform pioneered by Affymetrix, a California-based leader in the technology. The details of the agreement were reported today in the New York Times. The University Microarray Facility (UMF) plans a service menu that includes both the Affymetrix "chip" and the cDNA-spotting, custom glass slide-based technologies. The Center for Biotechnology (CBT) is advancing custom cDNA spotting microarray capabilities in this joint effort. Dr. Clinton Rubin, Director-CBT at Stony Brook, noted..."this joint effort will catalyze new approaches to questions of fundamental interest to the public and private sectors of biomedical research." "The current time-table seeks to place the Affymetrix system on line this summer, while the glass slide fabrication facility is being developed by the CBT," observed Dr. Craig Malbon, Vice-Dean for Scientific Affairs, School of Medicine. Dr. Malbon negotiated the agreement on behalf of Stony Brook to evolve to a regional core for microarray services. The UMF effort will be housed both in the newly-constructed Centers of Molecular Medicine and the new headquarters of the CBT on campus. Dr. Anil Dhundale, Director of Scientific Affairs - CBT, has been appointed
as Scientific Director of the UMF to organize the rapid development of
this exciting core facility. "The ability to perform large-scale and custom
gene profiling at Stony Brook will enable robust research grants and foster
economic development on Long Island," said Dr. Dhundale. Vice-President
for Research Gail Habicht enthusiastically supported the efforts to bring
this new technology to campus as a core facility available to the reseaarch
community. The University Microarray Facility expands the portfolio of
biomedical scientific cores, which includes campus-wide facilities for
microscopy & imaging, protein analysis (including MALDI mass spectroscopy),
tissue culture & hybridoma, transgenic mouse technology, mass spectrometry,
flow cytometry, biostatistical consultation, and DNA sequencing. Center for Biotech Opens in a Flurry of Praise Heavy snow was falling on Long Island January 20, but inside the new Center for Biotechnology facilities, Dr. Clinton Rubin and his staff basked in the glow of accomplishment. A crowd of 60 industry leaders braved the snow to celebrate the grand opening of the center's new location in the Psychology A building on the SUNY Stony Brook campus.
Speakers at the event included Shirley Strum Kenny, president of the university; NYBA's executive director, Karin Duncker; James Hayward, CEO of the Collaborative Group and a founding member of NYBA; and Steven Englebright, Suffolk County's state Assemblyman. Dr. Kenny opened the ceremony by congratulating the staff on their acheivements, which include forming NYBA and launching 40 start-up companies over 16 years. Assemblyman Englebright then presented Dr. Kenny with a proclamation from the New York Assembly. He added his own praise, saying that the Center was Long Island's future and the best of what public higher education can be. The Center's history and its role in founding New York Biotechnology Association were recalled by Karin Duncker. James Hayward spoke of the center's ontribution to Long Island's bioscience industry in general and to the Collaborative Group in particular. Over half his staff, he noted, had some connection to the Center for Biotechnology. As part of his presentation, Mr. Hayward unveiled the new web site of the Long Island Life Sciences Initiative (LILSI), www.lilsi.org. The Center is handling the ongoing administration of the initiative, a regional effort to develop national recognition for Long Island as a bioscience hub. The importance of the Center to Long Island and New York was highlighted in the address of Dr. Clinton Rubin, the Center's director. In 1998, the Center had an economic impact on the state of $86 million, twice that of any other state center for advanced technology. In its new location, Dr. Rubin promised, the center will expand its focus to encompass discovery and early stage technology development. With 20 technologies in various stages of development and 6 of those in advanced stages, the center has already become a virtual pharmaceutical company, he said. In closing, Dr. Rubin reminded the guests that translating academic research into economic benefit takes resources, and he hoped that the center proved worthy of continued support and investment. But with its impressive track record, influential supporters and a new, state-of-the-art research facility, the Center for Biotechnology can be sure of its future. The vision is up and running. (Newsday Article) back to top |
|
  |
